GeneDx Holdings Corp.
Financials
Valuation Metrics
GeneDx Holdings Corp.'s Market Cap is $2.05B. At end of 2025 it was $3.50B. Ranked #2033 of 3,114 in US market (top 65%), #775 of 1,472 on NASDAQ (top 53%), #126 of 203 in Health Care Equipment & Services (top 62%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.05B | US#2,033/3,114 Sec#126/203 |
| Revenue | $454M | US#2,281/3,114 Sec#144/203 |
| Net Income | $-106M | US—/3,114 Sec—/203 |
| Total Assets | $481M | US#2,773/3,114 Sec#159/203 |
| Net Assets | $244M | US#2,598/3,114 Sec#154/203 |
| Employees | 1,300 | US#1,885/3,114 Sec#126/203 |
| Value | ||
| P/B | 8.39x | US#2,502/3,114 Sec#155/203 |
| P/S | 4.51x | US#2,102/3,114 Sec#139/203 |
| FCF Yield | -3.70% | US—/3,114 Sec—/203 |
| Profitability | ||
| ROE | -43.55% | US#2,646/3,114 Sec#166/203 |
| ROA | -22.09% | US#2,812/3,114 Sec#180/203 |
| Op. Margin | -13.34% | US#2,543/3,114 Sec#161/203 |
| Revenue Growth | 25.42% | US#514/3,114 Sec#31/203 |
| Earnings Growth | -7664.51% | US#2,017/3,114 Sec#105/203 |
| Financial Health | ||
| Debt Ratio | 97.15% | US#1,067/3,114 Sec#101/203 |
| Total Debt | $167M | US#2,291/3,114 Sec#128/203 |
| FCF | $-76M | US#2,588/3,114 Sec#185/203 |
| Cash | $60M | US#2,497/3,114 Sec#158/203 |
| Current Ratio | 3.30x | US#694/3,114 Sec#70/203 |
| Performance | ||
| 1Y Return | -47.49% | US#2,879/3,114 Sec#185/203 |
| 1M Return | -4.50% | US#2,988/3,114 Sec#196/203 |
| From 52W High | -59.59% | US#2,905/3,114 Sec#193/203 |
| 1Y MDD | -79.40% | US#3,033/3,114 Sec#197/203 |
| Trading | ||
| Volume | 808,646 shares | US#1,514/3,114 Sec#98/203 |
| Trading Value | $56M | US#1,145/3,114 Sec#82/203 |
| Per Share | ||
| EPS | $-3.58 | US—/3,114 Sec—/203 |
| BPS | $8.23 | US#1,970/3,114 Sec#115/203 |
Company Info
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.